Table 1.
Summary of studies examining potential associations of PD-L1 expression levels with HCC clinicopathological characteristics and patient prognosis
| Study | Country | Sample size |
P-value
|
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gender | Age | AFP | Hepatitis history | Poor tumor differentiation | Tumor size | Satellite nodules | Vascular invasion | Tumor stage | OS | DFS/RFS | |||
| Finkelmeier et al14 | Germany | 215 | NR | NR | NR | >0.05 | NR | NR | NR | NR | <0.05 | <0.05 | NR |
| Gabrielson et al15 | USA | 65 | NR | NR | NR | >0.05 | >0.05 | NR | NR | >0.05 | >0.05 | 0.353 | NR |
| Gao et al16 | People’s Republic of China | 240 | >0.05 | >0.05 | >0.05 | >0.05 | >0.05 | >0.05 | >0.05 | <0.05 | >0.05 | <0.05 | <0.05 |
| Kan and Dong17 | People’s Republic of China | 128 | >0.05 | >0.05 | >0.05 | >0.05 | >0.05 | >0.05 | NR | <0.05 | >0.05 | <0.05 | NR |
| Umemoto et al18 | Japan | 80 | >0.05 | >0.05 | >0.05 | >0.05 | >0.05 | >0.05 | >0.05 | >0.05 | >0.05 | 0.051 | 0.081 |
| Wu et al19 | People’s Republic of China | 71 | NR | NR | NR | NR | NR | NR | NR | NR | NR | <0.05 | NR |
| Zeng et al20 | People’s Republic of China | 141 | >0.05 | >0.05 | >0.05 | NR | NR | <0.05 | >0.05 | <0.05 | <0.05 | <0.05 | <0.05 |
| Calderaro et al10 | France | 217 | >0.05 | >0.05 | <0.05 | >0.05 | <0.05 | >0.05 | <0.05 | <0.05 | NR | NR | <0.05 |
| Jung et al11 | Korea | 85 | >0.05 | >0.05 | >0.05 | >0.05 | >0.05 | <0.05 | NR | >0.05 | >0.05 | <0.05 | <0.05 |
| Shi et al12 | People’s Republic of China | 56 | NR | NR | NR | NR | NR | NR | NR | NR | <0.05 | NR | <0.05 |
| Wang et al13 | People’s Republic of China | 26 | >0.05 | >0.05 | NR | >0.05 | >0.05 | NR | NR | NR | <0.05 | NR | NR |
Note: Bold values are statistically significant.
Abbreviations: AFP, α-fetoprotein; DFS, disease-free survival; HCC, hepatocellular carcinoma; OS, overall survival; PD-L1, programmed death ligand 1; RFS, recurrence-free survival; NR, not reported.